Free Trial
CVE:TLT

Theralase Technologies (TLT) Stock Price, News & Analysis

Theralase Technologies logo
C$0.17 +0.01 (+3.03%)
As of 10:37 AM Eastern

About Theralase Technologies Stock (CVE:TLT)

Key Stats

Today's Range
C$0.17
C$0.18
50-Day Range
C$0.17
C$0.21
52-Week Range
C$0.14
C$0.38
Volume
37,611 shs
Average Volume
106,447 shs
Market Capitalization
C$41.40 million
P/E Ratio
N/A
Dividend Yield
1,705.88%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.

Receive TLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theralase Technologies and its competitors with MarketBeat's FREE daily newsletter.

TLT Stock News Headlines

Theralase Provides Corporate Update
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Theralase Technologies Inc.
Theralase Discovers New Mechanism of Action of Lead Drug
See More Headlines

TLT Stock Analysis - Frequently Asked Questions

Theralase Technologies' stock was trading at C$0.27 at the beginning of the year. Since then, TLT shares have decreased by 35.8% and is now trading at C$0.17.
View the best growth stocks for 2025 here
.

Shares of TLT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Theralase Technologies investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Alphabet (GOOG), Netflix (NFLX), Advanced Micro Devices (AMD) and JPMorgan Chase & Co. (JPM).

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
CVE:TLT
CIK
N/A
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-4,492,945.96
Net Margins
-438.78%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$1.02 million
Cash Flow
C$0.01 per share
Price / Cash Flow
30.45
Book Value
C$0.01 per share
Price / Book
18.65

Miscellaneous

Free Float
N/A
Market Cap
C$41.40 million
Optionable
Not Optionable
Beta
1.36
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (CVE:TLT) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners